Chan Henry Lee - Oct 8, 2025 Form 4 Insider Report for BeOne Medicines Ltd. (ONC)

Role
SVP, General Counsel
Signature
/s/ Qing Nian, as Attorney-in-Fact
Stock symbol
ONC
Transactions as of
Oct 8, 2025
Transactions value $
-$1,721,744
Form type
4
Date filed
10/10/2025, 04:56 PM
Previous filing
Sep 12, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lee Chan Henry SVP, General Counsel C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, SWITZERLAND /s/ Qing Nian, as Attorney-in-Fact 2025-10-10 0001980648

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ONC American Depositary Shares Sale -$389K -1.11K -100% $350.00 0 Oct 8, 2025 Direct F1, F2
transaction ONC American Depositary Shares Options Exercise $58.7K +302 $194.47 302 Oct 8, 2025 Direct F1
transaction ONC American Depositary Shares Options Exercise $1.91M +8.96K +2967.22% $213.32 9.26K Oct 8, 2025 Direct F1
transaction ONC American Depositary Shares Options Exercise $47.1K +296 +3.2% $159.03 9.56K Oct 8, 2025 Direct F1
transaction ONC American Depositary Shares Sale -$231K -664 -6.95% $347.82 8.9K Oct 8, 2025 Direct F1, F2
transaction ONC American Depositary Shares Sale -$1.66M -4.73K -53.21% $350.22 4.16K Oct 8, 2025 Direct F1, F2, F3
transaction ONC American Depositary Shares Sale -$1.46M -4.16K -100% $351.12 0 Oct 8, 2025 Direct F1, F2, F4
holding ONC Ordinary Shares 223K Oct 8, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ONC Share Option (Right to Buy) Options Exercise $0 -3.93K -9.01% $0.00 39.6K Oct 8, 2025 Ordinary Shares 3.93K $14.96 Direct F5, F6
transaction ONC Share Option (Right to Buy) Options Exercise $0 -116K -51.64% $0.00 109K Oct 8, 2025 Ordinary Shares 116K $16.41 Direct F5, F7
transaction ONC Share Option (Right to Buy) Options Exercise $0 -3.85K -2.94% $0.00 127K Oct 8, 2025 Ordinary Shares 3.85K $12.23 Direct F5, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each American Depositary Share represents 13 Ordinary Shares.
F2 The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2025.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.00 to $350.98, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.00 to $351.53, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F5 The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.
F6 These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
F7 These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
F8 These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.